PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33766591-2 2021 SARS-CoV-2 RNA dependent RNA polymerase (RdRp) which is almost preserved across different viral species can be a potential target for development of antiviral drugs, including nucleoside analogues (NA). Nucleosides 176-186 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 41-45 34303192-5 2021 Here, we screened non-nucleoside antivirals and found three out of them to be strongest in binding to RdRp out of which two retained binding even using molecular dynamic simulations. Nucleosides 22-32 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 102-106 34850656-0 2021 Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against RNA-Dependent RNA Polymerase Complex (nsp7/nsp8/nsp12) of SARS-CoV-2. Nucleosides 26-36 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 109-113 34850656-0 2021 Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against RNA-Dependent RNA Polymerase Complex (nsp7/nsp8/nsp12) of SARS-CoV-2. Nucleosides 26-36 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 114-118 34613689-4 2021 Far from merely being cautionary tales about the conduct of scientific research, these errors have had significant practical impact, by hampering a correct understanding of RdRp structure and mechanism, its inhibition by nucleoside analogues such as remdesivir, and the discovery and characterization of such analogues. Nucleosides 221-231 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 173-177 34517419-2 2021 Remdesivir, the broad-spectrum RdRp inhibitor acts as nucleoside-analogues (NAs). Nucleosides 54-64 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 31-35 33841878-1 2021 Background: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV2) depends on RNA-dependent RNA polymerase (RdRp) enzyme complex for its genomic replications and thus can be inhibited by nucleoside analogues. Nucleosides 192-202 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 113-117 34354677-4 2021 Nucleoside analogs are the most promising RdRp inhibitors and have shown effectiveness in vitro, as well as in clinical settings. Nucleosides 0-10 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 42-46 34354677-5 2021 One limitation of such RdRp inhibitors is the removal of incorporated nucleoside analogs by SARS-CoV-2 exonuclease (ExoN). Nucleosides 70-80 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 23-27 33556871-4 2021 The present article provides an overview of these small-molecule therapeutics based on insights from medicinal chemistry research and focuses on RNA-dependent RNA polymerase (RdRp) inhibitors, such as the nucleoside analogues remdesivir, favipiravir and ribavirin. Nucleosides 205-215 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 175-179 32943628-6 2020 The coronavirus RdRp complex represents an Achilles heel for SARS-CoV, supporting nucleoside analogues as promising candidates for the treatment of COVID-19. Nucleosides 82-92 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 16-20 33655751-2 2021 Nucleoside analogs such as Remdesivir and beta-d-N4-hydroxycytidine are antiviral candidates and may function as chain terminators or induce viral mutations, thus impairing RdRp function. Nucleosides 0-10 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 173-177 33655751-4 2021 To gain a structural understanding of the binding of this and several other nucleoside analogs in the precatalytic state, molecular models were developed that predict the noncovalent interactions to a complex of SARS-CoV-2 RdRp, RNA, and catalytic metal cations. Nucleosides 76-86 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 223-227 33755983-7 2021 Furthermore, we evidenced the ability of remdesivir, tenofovir, emtricitabine, and lamivudine to be incorporated in SARS-CoV-2 RdRp in the same protein pocket where poses the corresponding natural nucleoside substrates with comparable Ki and activating similar interactions. Nucleosides 197-207 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 127-131 32633831-5 2021 In this review, we discuss the antiviral potential of RdRp inhibitors (mainly nucleoside analogs) with an aim to provide a comprehensive account of drug discovery on SARS-CoV-2. Nucleosides 78-88 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 54-58 32836709-12 2021 While nucleoside analogs compete with the natural substrate of RdRp, thereby terminating RNA replication, other compounds would physically block entry of the natural substrates into the active site. Nucleosides 6-16 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 63-67 32821086-10 2020 The nucleoside analog inhibits the viral RNA-dependent RNA polymerase (RdRp) by competing with the usual counterpart adenosine triphosphate (ATP). Nucleosides 4-14 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 71-75 32283108-3 2020 To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogues (NAs), with over 25 approved for the treatment of several medically important viral diseases. Nucleosides 78-88 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 58-62 33020707-4 2020 In the present study, molecular recognition between the two natural nucleoside analogs (S-adenosyl-L-homocysteine (SAH) and sinefungin (SFG)) and the SARS-CoV-2 nsp16/nsp10/m7GpppAC5 was studied using all-atom molecular dynamics simulations and free energy calculations based on MM/GBSA and WaterSwap approaches. Nucleosides 68-78 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 167-172 32511380-6 2020 The coronavirus RdRp complex represents an Achilles heel for SARS-CoV, supporting nucleoside analogues as promising candidates for the treatment of COVID-19. Nucleosides 82-92 ORF1a polyprotein;ORF1ab polyprotein Severe acute respiratory syndrome coronavirus 2 16-20